Stock Market Reviews

MXCT (MaxCyte, Inc.) News

Get the latest news, insights, and market updates on MXCT (MaxCyte, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability
  ROCKVILLE, Md., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced a restructuring of its operations to better align resources with its strategic priorities. This plan includes a reduction of approximately 34% of the Company’s global workforce, inclusive of employees engaged through em
  Sep 22, 2025 - $MXCT
• MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio
  MaxCyte, Inc. (NASDAQ:MXCT) is one of the Best 52-Week Low Penny Stocks to Buy Now. On August 4, MaxCyte, Inc. (NASDAQ:MXCT) announced signing a strategic platform license with Adicet Bio, Inc. Adicet focuses on developing allogeneic gamma delta T cell therapies for cancer and autoimmune diseases. As part of this agreement, Adicet gets non-exclusive rights to […]
  Aug 11, 2025 - $MXCT
• MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance
  ROCKVILLE, Md., Aug. 06, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its second quarter ended June 30, 2025 financial results and updated its 2025 guidance. Second Quarter and Recent Highlights Core business revenue of $8.2 million in the second quarter of 2025, an increase of 8% over the
  Aug 6, 2025 - $MXCT
• MaxCyte, Inc. (MXCT) Reports Q2 Loss, Misses Revenue Estimates
  MaxCyte (MXCT) delivered earnings and revenue surprises of -20.00% and -14.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
  Aug 6, 2025 - $MXCT
• MaxCyte Signs Platform License Agreement with Adicet Bio
  MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support development of Adicet’s gamma delta T cell therapy gene edited programs ROCKVILLE, Md., Aug. 04, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced it has signed a strategic platform license (SPL) with Adicet Bio, I
  Aug 4, 2025 - $MXCT
• MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline
  MaxCyte’s Flow Electroporation® Technology will support non-viral gene editing in the manufacture of Anocca’s TCR-T cell therapiesROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced the signing of a Strategic Platform License Agreement (SPL) with Anocca AB, a leadin
  Jul 31, 2025 - $MXCT
• MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025
  ROCKVILLE, Md., July 09, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the second quarter 2025 after the U.S. market close on Wednesday, August 6th, 2025. Company management will host a conference call to discuss financial results at 4:30 p.m. East
  Jul 9, 2025 - $MXCT
• PHC Announces Exclusive Distribution of MaxCyte® ExPERT™ Platform in Japan
  TOKYO, July 01, 2025--The Biomedical Division of PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereafter referred to as "PHCbi"), a subsidiary of PHC Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo, hereafter referred to as "PHCHD") announces it has signed an exclusive agreement with MaxCyte, Inc. to distribute the MaxCyte ExPERT platform(*1) in Japan. In Singapore, SciMed (Asia) Pte Ltd, a subsidiary of PHCHD, separately entered into an exclusive distribut
  Jul 1, 2025 - $MXCT
• MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
  MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten manufacturing timelinesROCKVILLE, Md. and LONDON, June 11, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, and Oribiotech Ltd. (Ori), a leader in advanced cell and
  Jun 11, 2025 - $MXCT
• MaxCyte, Inc. (MXCT): A Bull Case Theory
  We came across a bullish thesis on MaxCyte, Inc. (MXCT) on Substack by OppCost. In this article, we will summarize the bulls’ thesis on MXCT. MaxCyte, Inc. (MXCT)’s share was trading at $2.355 as of May 9th. MaxCyte, Inc. is a commercial-stage cell-engineering company with a strong strategic position in the rapidly growing cell and gene therapy […]
  May 13, 2025 - $MXCT